Fundraising FoxNKore Biotherapeutics
Germantown, US · Founded 2020 · Delaware LLC
Find your way into NKore Biotherapeutics
Sign up to see every warm intro you have to NKore Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NKore Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NKore BioTherapeutics is a cellular-based biotherapeutics company developing an allogeneic immunotherapy platform based on a proprietary method of activating natural killer (NK) cells, called Supercharged NK (sNK) cells. Its lead therapy, NK101, targets solid and blood cancers in adult and pediatric patients, with human clinical trials planned in the United States beginning in 2027.
Founders & leadership
NKore Biotherapeutics was founded in 2020 by Anahid Jewett.
Board
Reported raises · per SEC filings
Form D private placements$250K disclosed across 1 round · 2023
▶$250KraisedApr 2023 · 2 investors · BiotechnologyRule 506(b)
- R Gregory BrophyExecutive Officer, Director
- Tracy RyanExecutive Officer, Director
- Timothy BrahmDirector
- Diederik van der ReijtDirector
- Offering amount
- $3M
- Amount sold
- $250K
- Minimum investment
- $25K
- Proceeds to insiders
- $11.5K
- First sale
- Mar 2023
- Incorporated
- Limited Liability Company, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as NKore Biotherapeutics.
Frequently asked questions
- What does NKore Biotherapeutics do?
- NKore BioTherapeutics is a cellular-based biotherapeutics company developing an allogeneic immunotherapy platform based on a proprietary method of activating natural killer (NK) cells, called Supercharged NK (sNK) cells. Its lead therapy, NK101, targets solid and blood cancers in adult and pediatric patients, with human clinical trials planned in the United States beginning in 2027.
- Who founded NKore Biotherapeutics?
- NKore Biotherapeutics was founded by Anahid Jewett in 2020.
- How much funding has NKore Biotherapeutics raised?
- NKore Biotherapeutics has disclosed $250K raised across 1 round.
- Where is NKore Biotherapeutics headquartered?
- NKore Biotherapeutics is headquartered in Germantown, US.